01 The increasing focus on allogeneic and autologous therapies, technological innovations in cell manufacturing and delivery, supportive regulatory frameworks, and strategic collaborations among biotechnology, pharmaceutical companies, and contract development and manufacturing organizations (CDMOs), further drive the cell therapy industry growth.Moreover, the expansion of cell therapy applications across oncology, cardiovascular, musculoskeletal, and other therapeutic areas is accelerating market adoption worldwide. Furthermore, initiatives by government agencies and non-profit organizations to improve access to innovative therapies, combined with the integration of advanced manufacturing technologies such as automation and 3D bioprinting, are further driving market growth. The growing investment in R&D, partnerships, and clinical trials for next-generation cell therapies is also strengthening the market’s long-term potential, positioning it as a transformative segment within the global healthcare industry.
01 Shift from Traditional Cell Therapy to 3D Bio-Printed, Patient-Specific Treatments Cell therapy is moving from conventional methods, which rely on standard cell culture and transplantation, to advanced 3D bioprinting approaches that enable the fabrication of complex, patient-specific tissue structures. For example, in March 2024, as per the article published in Elsevier B.V., researchers at the University of California, San Diego, developed a 3D-printed scaffold seeded with stem cells to repair heart tissue damaged by myocardial infarction, demonstrating improved tissue regeneration and integration with native heart muscle. This shift highlights a move toward more personalized and effective cell-based therapies, which further enhances the market growth.
02 Adoption of Advanced Stem Cell Therapies in Asia The cell therapy landscape in Asia is evolving with the growing development and adoption of mesenchymal stem cell (MSC) therapies. For example, in 2025, as per the American Society of Gene + Cell Therapy, China’s NMPA approved the country’s first mesenchymal stem cell therapy, Platinum Life’s Ruibosheng, indicated for steroid-refractory acute graft-versus-host disease. Such a factor reflects a broader trend of integrating advanced stem cell therapies into clinical practice across the region, expanding treatment options for patients with previously limited alternatives.
June 2026 Bristol Myers Squibb expanded its cell therapy manufacturing and development capabilities through continued investments in advanced therapy production facilities. The expansion supports increased capacity for personalized cell therapies, including CAR-T treatments for cancer.
March 2026 Novartis expanded its cell therapy operations with enhanced manufacturing and digital capabilities to support next-generation CAR-T therapies. The initiative strengthens production efficiency and global access to personalized oncology treatments.
January 2026 Kite Pharma expanded its cell therapy manufacturing network through facility upgrades and process improvements. The expansion supports increased production capacity for approved CAR-T therapies and future pipeline candidates.
October 2025 Vertex Pharmaceuticals expanded its cell therapy development programs following progress in stem cell-derived therapies for chronic diseases. The company continued advancing scalable manufacturing approaches for regenerative medicine applications.